How the type of risk reduction influences required sample sizes in randomised clinical trials
| Autor: | D. van der Heijde, Robert Landewé, Astrid J. B. Wanders, K Bruynesteyn |
|---|---|
| Přispěvatelé: | Other departments |
| Rok vydání: | 2004 |
| Předmět: |
Relative risk reduction
medicine.medical_specialty business.industry Patient Selection Immunology Hypothesis Individual risk General Biochemistry Genetics and Molecular Biology Outcome (probability) Statistical power law.invention Clinical trial Randomized controlled trial Rheumatology Sample size determination law Sample Size Physical therapy medicine Immunology and Allergy Humans Risk factor business Randomized Controlled Trials as Topic |
| Zdroj: | Annals of the rheumatic diseases, 63(11), 1368-1371. BMJ Publishing Group |
| ISSN: | 0003-4967 |
| Popis: | To increase change between groups, randomised clinical trials (RCT) often include patients with high risk for a particular outcome, by inclusion criteria that select predictors for that outcome. This increases the statistical power, and fewer patients are required for that RCT. The way in which patient selection influences the power, and thus sample size required, depends on how an intervention reduces the individual risk: by an absolute or relative risk reduction model. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|